Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up

Marieke van Horck · Bjorn Winkens · Geertjan Wesseling · Karin de Winter-de Groot · Ilja de Vreede · Quirijn Jöbsis · Edward Dompeling

Original Article

Abstract There are limited data on health-related quality of life (HRQoL) changes over time in children with cystic fibrosis (CF). We investigated associations between clinical and treatment variables with changes in HRQoL during 1 year. Forty-nine children with CF aged 6–18 years were followed in this multicentre, observational cohort study during 1 year. HRQoL was measured by the validated disease specific cystic fibrosis questionnaire-revised (CFQ-R). The CFQ-R total score as well as most domain scores improved significantly (8.0 points and [3.3–31.7] points respectively) during the one-year follow-up. Age at baseline demonstrated a strong longitudinal association with the change of CFQ-R total score (2.853 points decrease of CFQ-R total score per year increase in age) and several domain scores. Below 12 years of age, CFQ-R total score improved in most children, whereas a deterioration was observed in most children above 12 years. The number of PEx was associated with an increase of treatment burden score (4.466 points decrease per extra PEx).

Conclusion: In the group as a whole, HRQoL improved significantly over time. However, changes over time were significantly influenced by age: below 12 years of age, HRQoL improved in most patients whereas a deterioration was observed in most children >12 years. Strategies how to preserve or ideally to improve HRQoL in adolescence should be developed.

What is known:

• Quality of life in patient with CF is diminished
• Although CF is a chronic disease, longitudinal data on QoL in children with CF are scarce.

What is new:

• Below 12 years of age, quality of life improved in most children during the 1-year follow-up whereas a deterioration in quality of life was observed in most children above 12 years.
• the treatment burden score of QoL correlated with the exacerbation rate
Introduction

Survival in cystic fibrosis (CF) has improved drastically over the past decades but is also accompanied by more CF-related comorbidities and a greater treatment burden, which may impact quality of life [17]. Quality of life in a chronic disease like CF is not only of major importance to patients but also to the treating physicians. Fortunately, in the management of CF, there is an increasing focus on survival in combination with a good health-related quality of life (HRQoL) [18]. Moreover, HRQoL is increasingly used as a patient-related-outcome measure for clinical trials in patients with CF [8]. Clinicians should be able to assess both the medical benefit and the contribution to quality of life of (new) treatments for each individual patient [18]. Hence, it is important to identify factors associated with HRQoL, so clinicians can focus on prioritizing and optimizing management of factors that impact it at the most [9]. The cystic fibrosis questionnaire-revised (CFQ-R) is a disease specific, validated HRQoL measure [14].

Most research on quality of life in CF is performed in adults and has a cross-sectional study design, whereas the majority of longitudinal studies on HRQoL was conducted in clinical trials of CF therapies. Longitudinal data on HRQoL in non-intervention studies with children are currently lacking. Several cross-sectional studies showed that age, gender, body mass index (BMI), pulmonary exacerbations (PEx), and forced expiratory volume in 1 s (FEV$_1$) appear to impact HRQoL as measured by the CFQ-R [4, 10, 11, 16].

Sawicki et al. demonstrated significant associations between respiratory symptoms and CFQ-R respiratory symptom scores and between weight and scores on CFQ-R nutritional health domains in children and adults during 9–15 months of follow-up [20].

In this prospective observational study during 1 year, we investigated associations between clinical and treatment variables with changes in CFQ-R scores in children with CF. We assumed that (1) pulmonary exacerbations and lung function decline are related to worsening of CFQ-R respiratory health domains; (2) the number of medications/inhalation therapies are associated with higher CFQ-R treatment burden scores.

Methods

Study design and patients

Children with CF aged 5 to 19 years were included in this 1-year, multicentre, observational cohort study (clinicaltrial.gov NCT01241890). Children were recruited from three CF centers in the Netherlands (Maastricht, Utrecht, and Amsterdam).

CF was defined as the presence of characteristic clinical features (persistent pulmonary symptoms, meconium ileus, failure to thrive, and steatorrhea) in combination with an abnormal sweat test (chloride >60 mM) and/or two CF mutations [21]. Exclusion criteria were (1) severe cardiac abnormalities; (2) mental disability; (3) no technically adequate performance of measurements; (4) on waiting list for lung transplantation; (5) children colonized with *Burkholderia cepacia* or *Methicillin-resistant Staphylococcus aureus*; (6) participation in an intervention trial.

Children with *B. cepacia* or MRSA were excluded as part of the study (not reported here) included breath measurements (exhaled volatile organic compounds and cytokines in exhaled breath condensate) which have a risk of cross-infection of other patients by the breath sampling equipment. Ethical approval was obtained from the Medical Ethical Committee of the Maastricht University Medical Centre. Informed consent was signed by all parents, and by children aged 12 years and over.

Study parameters

For the period of 1 year, all children attended regular clinical visits every 2 months. Demographic information and clinical characteristics (pancreatic insufficiency [use of pancreatic enzymes], BMI z scores, and colonization with *Pseudomonas aeruginosa*) were collected at inclusion. During each clinical visit, changes in treatment/medications were reported (total number of medications, number of inhalation therapies [such as DNA-se, hypertonic saline, or antibiotic], and use of insulin). Besides, dynamic lung function parameters (Masterscreen Pneumo, Carefusion, Houten, The Netherlands) were assessed according to international standards [13]. Recorded parameters were FEV$_1$, forced vital capacity (FVC), and maximum expiratory flow at 50% of FVC (MEF$_{50}$), all expressed as absolute...
rate and as percentage of the predicted normal value. Children and their parents were asked to fill in the CFQ-R questionnaire three times during the study, at inclusion, after 6 months and after 1 year of follow-up. We defined change in CFQ-R scores during 1 year as main outcome measure (excluding CFQ-R scores filled in after 6 months). We used the translated and validated Dutch CFQ-R questionnaires appropriate for the different age groups [11]: 6–13 years (child interview), 13–14 years of age (child self-report), and ≥14 years (adolescents). Furthermore, parents of children aged 6–13 years reported on a special parent version. The CFQ-R consists of 35–50 items divided into 7–9 domains (depending on age group): physical functioning, energy and well-being, emotional state, social limitations, role limitations, body image, eating disturbances, treatment burden, and embarrassment. Moreover, overall health perception and three symptom scales are included: respiratory, digestive, and weight. Items require either a frequency response on a 4-point scale (‘all the time’ to ‘never’), a difficulty rating on a 4-point scale (‘a lot of difficulty’ to ‘no difficulty’), a true–false rating on a 4-point scale, or the selection of a statement that describes the patient (on a 3- or 4-point scale). The scores range from 0 to 100 with higher scores corresponding to higher quality of life. Only for the respiratory symptom domain, a minimal clinically important difference (MCID), the smallest clinically relevant change a patient can detect, of 4.0 points (in stable patients) is determined [15]. For the analysis of the separate domains, only those completed by all age groups were included (excluding energy and well-being, role limitations, embarrassment, and the weight symptom scale). The main outcome was changed in CFQ-R total and domain scores in 1 year.

PEx were defined by courses of therapeutic antibiotics (intravenous and oral) prescribed by the responsible paediatric pulmonologists, considering the clinical symptoms as an expression of a PEx. PEx were treated according to the Dutch Central Guidance Committee (CBO) guideline [5], which resembles European [21] and American CF guidelines [7].

Statistical analysis

Descriptive statistics of the baseline characteristics were expressed as mean (standard deviation [SD]) or as median (interquartile range [IQR], i.e. 25th–75th percentile) for numerical variables, and as number (percentage) for categorical variables. Differences between those children with one or more missing covariate and/or outcome value and those included in the complete case analysis (CCA) were tested using independent-samples t test or Mann-Whitney U test for numerical variables and chi-square test for categorical variables.

To analyse the associations between demographic and clinical characteristics and changes in CFQ-R scores (T = 12 minus T = 0), univariable and multivariable linear regression models were used. Dependent variables for the models were changed in CFQ-R total score and CFQ-R domain scores. All covariates (demographic and clinical characteristics) with a p value ≤0.20 from the univariable analyses were entered in the multivariable analysis.

To deal with missing data, 50 complete datasets were created using multiple imputation (MI). The maximum number of iterations was set equal to 20, where convergence was checked by inspecting the trace lines. The missing covariate and outcome values were imputed using all other variables as predictors, where the outcome variable was included to impute missing covariate values. The CCA, in which the patients with one or more missing covariate values were excluded from the analysis, was also performed and served as a sensitivity analysis.

Data were analysed with IBM SPSS Statistics for Windows (version 22.0. Armonk, NY). The multiple imputation part was performed using the MICE package in R (version 3.2.3) [23].

A post-hoc power analysis showed that with 49 cases, correlations between changes in CFQ-R scores and clinical variables of ≥0.30 can be detected with a power of 0.80 and a significance level α of 0.05, which was evaluated as sufficiently accurate for the purpose of this clinical study.

Results

Forty-nine patients participated in this 1-year prospective observational study. For the analysis of HRQoL, 39 of them (80%) had no missing values (covariates and outcome parameters) and were included in the CCA. Table 1 shows the baseline demographic and clinical characteristics of all 49 children and of the two subgroups, i.e. those without CCA and those with any missing covariates or outcome variables (‘missing’). There were no significant differences between those in the CCA and those in the ‘missing’ group.

Course of CFQ-R scores

Table 2 shows the mean CFQ-R total score and domain scores at T = 0, T = 12, and the change from baseline during follow-up. All scores improved significantly during the year except digestive symptoms. The mean total CFQ-R score was 68.6 at T = 0 and 76.6 at T = 12, a significant improvement of 8.0 points. Almost all domain scores also improved significantly, from 3.3 points (respiratory symptoms domain) to 31.7 points (physical functioning domain).

Associations with change in CFQ-R total score

The MI analyses showed that, after correction for the other covariates, only age at baseline had a strong longitudinal association with change of CFQ-R total score in 1 year (Table 3). The estimate (B) indicates that with every year a child gets older, the mean change from baseline in CFQ-R
The total score decreased with 2.853. The relationship between PEx and the change in CFQ-R total score was of borderline significance ($p = 0.065$). Sex, BMI $z$ score, pancreas insufficiency at $T = 0$, number of medications during the study, CFRD at $T = 0$, pathology of the upper respiratory tract at $T = 0$, and CFQ total score at $T = 0$ were not included in the MI (all $p$ values from univariable analyses were $\geq 0.20$).

Similar results were found in de CCA. No correlation between the change in HRQoL and the change in FEV1 was found ($\text{Pearson correlation coefficient } r = 0.036, p = 0.83$).

Figure 1 shows the association between age at baseline and CFQ-R total scores of the CCA.

### Associations with change in separate CFQ-R domain scores

In the multivariable regression models of the separate CFQ-R domains, increase in age was consistently associated with worsening of physical functioning and social functioning domain scores, treatment burden score, and respiratory symptoms score (Table 4). Of the other covariates, the number of PEx was independently associated with increasing treatment burden score, whereas the total number of (non-inhalation) therapies was associated with worsening of physical functioning domain score. In contrast, multivariable regression models

### Table 1 Baseline characteristics of the 49 children

| Characteristic                              | Total cohort ($n = 49$) | CCA ($n = 39$) | ‘missing’ ($n = 10$) | $p$ value |
|---------------------------------------------|------------------------|----------------|---------------------|-----------|
| Age, mean (SD)                              | 10.3 (3.6)             | 10.3 (3.2)     | 10.3 (4.9)          | 0.984     |
| Male sex, $N$ (%)                           | 31 (63.3)              | 26 (66.7)      | 5 (50.0)            | 0.329     |
| Pseudomonas Aeruginosa at inclusion*, $N$ (%) | 15 (30.6)              | 12 (30.8)      | 3 (30.0)            | 0.962     |
| Pancreatic insufficiency, $N$ (%)            | 32 (65.3)              | 25 (64.1)      | 7 (70.0)            | 0.727     |
| CFRD                                         | 4 (8.2)                | 4 (10.3)       | 0 (0.0)             | 0.291     |
| Pathology of upper respiratory tract         | 21 (42.9)              | 16 (41.0)      | 5 (50.0)            | 0.609     |
| FEV1, % of predicted value, mean (SD)        | 87.4 (18.1)            | 87.1 (17.5)    | 88.6 (21.2)         | 0.816     |
| BMI $z$ score, mean (SD)                     | 0.14 (0.83)            | 0.17 (0.81)    | 0.05 (0.94)         | 0.675     |
| Number of PEx, median (IQR)                  | 2.0 (1.0–4.0)          | 2.0 (1.0–4.0)  | 1.0 (0.0–3.3)       | 0.384     |
| Number of medications$^b$, median (IQR)     | 7.0 (5.0–9.0)          | 7.0 (5.0–9.0)  | 6.0 (4.8–7.5)       | 0.320     |
| Number of inhalation therapies, median (IQR) | 2.0 (1.0–2.0)          | 2.0 (1.0–3.0)  | 1.5 (1.0–2.0)       | 0.687     |

**BMI** body mass index, **CFRD** cystic fibrosis-related diabetes, **FEV1** forced expiratory volume in 1 s, **FVC** forced vital capacity, **PEx** pulmonary exacerbations

$^a$Treated because of the presence in sputum

$^b$Total number of medications minus total number of inhalation therapies

### Table 2 CFQ-R total and domain scores at $T = 0$ and $T = 12$ and change over time

| Characteristic                              | $T = 0$, mean (SD) | $T = 12$, mean (SD) | Change ($T = 12$–$T = 0$), mean (SD) | $p$ value |
|---------------------------------------------|-------------------|---------------------|--------------------------------------|-----------|
| CFQ-R total score, mean (SD)                | 68.6 (11.1)       | 76.6 (9.8)          | 8.0 (16.3)                           | <0.001*   |
| CFQ-R physical functioning, mean (SD)       | 48.5 (31.8)       | 80.2 (16.6)         | 31.7 (41.3)                          | <0.001*   |
| CFQ-R emotional functioning, mean (SD)      | 76.3 (12.0)       | 82.1 (11.0)         | 5.8 (11.2)                           | <0.001*   |
| CFQ-R social functioning, mean (SD)         | 61.5 (17.0)       | 73.3 (17.8)         | 11.8 (27.5)                          | <0.001*   |
| CFQ-R body image, mean (SD)                 | 82.0 (21.2)       | 91.6 (10.8)         | 9.6 (19.2)                           | <0.001*   |
| CFQ-R eating disturbances, mean (SD)        | 70.5 (17.9)       | 76.5 (26.5)         | 6.0 (24.0)                           | <0.001*   |
| CFQ-R treatment burden, mean (SD)           | 61.6 (20.6)       | 69.6 (24.7)         | 8.0 (36.6)                           | <0.001*   |
| CFQ-R respiratory symptoms, mean (SD)       | 79.3 (14.6)       | 82.6 (12.0)         | 3.3 (16.0)                           | <0.001*   |
| CFQ-R digestive symptoms, mean (SD)         | 69.5 (23.2)       | 68.7 (24.6)         | −0.8 (32.9)                          | 0.211     |
| FEV1, % of predicted value, mean (SD)       | 87.1 (17.5)       | 87.1 (19.0)         | −0.03 (10.8)                         | 0.987     |

**CFQ-R** cystic fibrosis questionnaire-revised

$^a$p < 0.05
did not show significant associations with any covariate and changes in the domains of emotional functioning, eating disturbances, body image, and digestive symptoms.

**Discussion**

In this 1-year observational study, we investigated longitudinal associations between clinical and treatment variables with changes in HRQoL in children with CF. Overall, CFQ-R total score and all domain scores, except the digestive symptom score, improved significantly during 1 year. An older age was the most important determinant of a deterioration in CFQ-R total score and in several domain scores, whereas the CFQ-R total score improved in most children <12 years. Furthermore, PEx were significantly related to an increase in treatment burden score, and the total number of non-inhalation therapies correlated with a deterioration of the physical functioning domain score during 1 year.

To our knowledge, this is the first longitudinal non-intervention study in children with CF to investigate the impact of clinical and treatment variables on change in HRQoL. We found significant improvements in CFQ-R total scores as well as most domain scores. We speculate that merely participating in an intensive study like the present one improves HRQoL because of the extra attention that patients get, the extra contacts with the nurses and physicians of the CF team, and maybe also a better treatment adherence during the study. An alternative explanation for the main findings (Fig. 1) may be a better coping with the disease in the course of years after birth (during school age) and the problems related to CF in teenagers. It is interesting to perform in depth/focus interviews with parents and children with CF to get a better idea about underlying reasons for changes in HRQoL. The drop in QoL in children of 12 years and over may be the consequence of the increasing disease severity and treatment intensity, as reflected by the scores of the treatment burden domain and the respiratory symptom domain. Our results are in accordance with Abbott et al. who showed a significant deterioration of all CFQ-R domain scores in adolescents and adults during a decade of follow-up (−6.0 to −15.9 points) [2]. In children (6–13 years of age), Sawicki et al. found a significant increase in respiratory symptom score over 1 year, but no significant changes in the other domains [20]. In adults, Dill et al. found that although individual variation exists, overall, there was no significant change in physical HR-QoL during 21 months of follow-up [6]. However, there were significant time trends in three psychosocial domains: treatment burden (improvement), emotional functioning (improvement), and social functioning (deterioration) [6].

Others also found an effect of age on HRQoL. Hegarty et al. demonstrated that children aged 6–13 years scored significantly better than those aged 14–18 for ‘emotional state’, ‘body image’, and ‘treatment burden’ [10]. Moreover, a large European study in healthy children found a gradual decrease in HRQoL from childhood into adolescence [12]. Abbott et al. evaluated the relationship between demographic and clinical variables and HRQoL during a 12-year period in adolescents and adults. In this study, the importance of advancing age as predictor of HRQoL was confirmed [3]. Especially in children with CF, not much is known about ‘normal’ CFQ-R scores. The HRQoL Outcomes Group warns about the difficulty of interpreting changes in CFQ-R scores; there is no minimal clinically important difference known for the CFQ-R scores.


Table 4  Associations between demographic/clinical variables and changes in CFQ-R domains (only results of multivariable analyses are shown)

| Covariate                                      | Physical functioning (B, CI, p value) | Social functioning (B, CI, p value) | Treatment burden (B, CI, p value) | Respiratory symptoms (B, CI, p value) |
|------------------------------------------------|---------------------------------------|------------------------------------|----------------------------------|--------------------------------------|
| Age at T = 0                                    | -3.766 (-6.565, -0.967) 0.008*        | -4.188 (-6.150, -2.226) <0.001*    | -6.995 (-9.401, -4.589) <0.001*   | -1.450 (-2.859, -0.41) 0.044*        |
| BMI z-score at T = 0                           | 0.102 (-10.576, 10.780) 0.985         | 1.531 (-7.047, 10.137) 0.727        | a)                               | -4.280 (-10.301, 1.742) 0.163        |
| FEV1% pred at T = 0                            | 0.120 (-0.400, 0.640) 0.650           | a)                                 | a)                               | a)                                   |
| Number of PEx during study                     | -3.818 (-8.092, 0.453) 0.080          | -2.352 (-5.748, 1.044) 0.175        | -4.466 (-8.821, -0.111) 0.044*    | a)                                   |
| Pancreas insufficiency at T = 0                | -11.219 (-24.839, 2.402) 0.106        | a)                                 | a)                               | a)                                   |
| Number of medications during study             | -4.097 (-7.254, -0.940) 0.011*        | a)                                 | a)                               | a)                                   |
| Number of inhalation therapies during study    | 1.079 (-7.107, 9.265) 0.796           | a)                                 | a)                               | a)                                   |
| CFRD at T = 0                                  | -7.219 (-38.890, 24.452) 0.655        | a)                                 | a)                               | a)                                   |
| Pathology of upper respiratory tract at T = 0  | -7.758 (-21.648, 6.133) 0.274         | a)                                 | a)                               | 0.974 (-0.271, 18.410) 0.057         |
| CFQ-R domain score at T = 0                    | -1.396 (-2.080, -0.711) <0.001*       | a)                                 | a)                               | -0.297 (-0.701, 0.107) 0.149         |

a) not included in multivariable analyses (p values from univariable analyses were >0.20)

BMI body mass index, CFRD cystic fibrosis-related diabetes, CFQ cystic fibrosis questionnaire-revised, FEV1% pred forced expiratory volume in 1 s as percentage of predicted, PEx pulmonary exacerbations

*p < 0.05

Total number of medications minus total number of inhalation therapies

except for the respiratory symptom domain [1, 15]. Tibosch et al. found that the majority of healthy children do not reach the maximum scores on many domains of the CFQ-R [22]. This implies normal psychosocial development and puberty should be taken into account when interpreting HRQOL, especially in childhood and adolescence [22]. We hypothesised that CFQ-R treatment burden (measured as non-inhalation) and treatment burden scores would be influenced by the number of medications and treatment time. Furthermore, we speculated that CFQ-R treatment burden (measured as non-inhalation) and treatment burden scores would be influenced by the number of medications and treatment time. Additionally, we found no significant relationship between number of medications and treatment burden scores. Zian et al. followed up the relatively preserved and stable FEV1% pred during the follow-up period of only 1 year. The strengths of our study are the longitudinal study design, the focus on children only, and assessing HRQOL specifically in a non-interventional study. Although the power analysis showed that clinically meaningful correlations were detected with this relatively small sample size, it was still a limitation that a temporary increase in number of medications and/or treatment time due to the exacerbation does matter. The strengths of our study are the longitudinal study design, the focus on children only, and assessing HRQOL specifically in a non-interventional study. Although the power analysis showed that clinically meaningful correlations were detected with this relatively small sample size, it was still a limitation that a temporary increase in number of medications and/or treatment time due to the exacerbation does matter.
at random. In this study group, the percentage of children with pancreas insufficiency (65%) was lower than in the national Dutch cohort (80–90% pancreas insufficiency). The results of this study may not hold for children with *B. cepacia* or MRSA patients as they were not included in this study. Although statistically significant improvements were observed in most QoL scores over time, these changes may not be clinically meaningful as MCID of most QoL scores is unknown.

The clinical implication of our study is that age and puberty have impact on HRQoL. Longitudinal changes in HRQoL in children with CF are relevant, and HRQoL may therefore at least be included in the annual clinical evaluation of patients. It is worthwhile to repeat the study in a larger cohort and to assess more background information about experiencing a better or worse HRQoL, for instance by focus interviews. Besides, strategies to improve HRQoL in children with CF are very important, particularly in teenagers.

In conclusion, an older age is by far the most important variable related to a deterioration in HRQoL in children with CF. Besides, PEx and number of inhalation therapies were related to treatment burden and physical functioning. This means physicians should focus on HRQoL in adolescents and develop strategies on how to preserve or even improve HRQoL in this age group.

Acknowledgements The authors thank all the children and parents for taking part in this study. Besides, this study could not be carried out without the outstanding efforts of Sylvia Esten, Sabine Michel, Eltje Bloemen, Margreet Polman, Saeeda Lone, and Nora Adriaens who were responsible for the performance of the clinical visits. We also want to thank the medical students Myrthe Kersemaekers, Sanne Vaassen, Myrthe Berkhof, Sjoerd Gulikers, and Elles Broen for their great assistance during this study.

Authors’ contributions ED and QJ developed the study and wrote the grant application. MvH and BW interpreted the results and drafted the manuscript. BW executed the statistical analyses. GW, BW, KdW, IdV, ED, and QJ coordinated the data collection, interpreted the results, and supervised drafting the manuscript. MvH coordinated the database of the three CF centres in the Netherlands. All authors contributed to and approved the final draft for publication.

Compliance with ethical standards

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Funding This study was funded by the Dutch CF Foundation and Chiesi Pharmaceuticals bv.

Conflict of interest The authors declare that they have no conflict of interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Abbott J, Hart A, Havermans T, Matossian A, Goldbeck L, Barreto C et al (2011) Measuring health-related quality of life in clinical trials in cystic fibrosis. J Cyst Fibros 10(Suppl 2):S82–S85
2. Abbott J, Hurley MA, Morton AM, Conway SP (2013) Longitudinal association between lung function and health-related quality of life in cystic fibrosis. Thorax 68(2):149–154
3. Abbott J, Morton AM, Hurley MA, Conway SP (2015) Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis. BMJ Open 5(5):e007418
4. Casier A, Goubert L, Theunis M, Huse D, De Baets F, Matthys D et al (2011) Acceptance and well-being in adolescents and young adults with cystic fibrosis: a prospective study. J Pediatr Psychol 36(4):476–487
5. CBO (2007) Richtlijn diagnostiek en behandeling van cystische fibrose
6. Dill EJ, Dawson R, Sellers DE, Robinson WM, Sawicki GS (2013) Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest 144(3):981–989
7. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ et al (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180(9):802–808
8. Goss CH, Quittner AL (2007) Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 4(4):378–386
9. Habib AR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS (2015) A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc 12(3):420–428
10. Hegarty M, Macdonald J, Watter P, Wilson C (2009) Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. Child Care Health Dev 35(4):462–468
11. Klijn PH, van Stel HF, Quittner AL, van der Net J, Doelman W, van der Schans CP et al (2004) Validation of the Dutch cystic fibrosis questionnaire (CFQ) in adolescents and adults. J Cyst Fibros 3(1):29–36
12. Michel G, Bisegger C, Fuhr DC, Abel T, group K (2009) Age and gender differences in health-related quality of life of children and adolescents in Europe: a multilevel analysis. Qual Life Res 18(9):1147–1157
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al (2005) Standardisation of spirometry. Eur Respir J 26(2):319–338
14. Quittner AL, Bux A, Messer MA, Modi AC, Watrous M (2005) Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128(4):2347–2354
15. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB (2009) Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients
with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135(6):1610–1618
16. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A et al (2012) Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res 21(7):1279–1290
17. Quon BS, Aitken ML (2012) Cystic fibrosis: what to expect now in the early adult years. Paediatr Respir Rev 13(4):206–214
18. Royce FH, Carl JC (2011) Health-related quality of life in cystic fibrosis. Curr Opin Pediatr 23(5):535–540
19. Sawicki GS, Sellers DE, Robinson WM (2009) High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 8(2):91–96
20. Sawicki GS, Rasouliyan L, McMullen AH, Wagener JS, McColley SA, Pasta DJ et al (2011) Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 46(1):36–44
21. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P et al (2014) European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros 13(Suppl 1):S23–S42
22. Tibosch MM, Sintnicolaas CJ, Peters JB, Merkus PJ, Yntema JB, Verhaak CM et al (2011) How about your peers? Cystic fibrosis questionnaire data from healthy children and adolescents. BMC Pediatr 11:86
23. van Buuren S, Groothuis-Oudshoorn K (2011) Mice: multivariate imputation by chained equations in R. J Stat Softw 45(3):1–67
24. Ziaian T, Sawyer MG, Reynolds KE, Carbone JA, Clark JJ, Baghurst PA et al (2006) Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma. J Paediatr Child Health 42(10):596–600